Prevalence, risk factors and treatment outcomes of isoniazid resistant TB in Bulawayo city, Zimbabwe: A cohort study | Zendy

Barbara Manyame-Murwira | Zendy; Kudakwashe Collins Takarinda | Zendy; Pruthu Thekkur | Zendy; Bright Payera | Zendy; Herbert Mutunzi | Zendy; Raiva Simbi | Zendy; Nicholas Siziba | Zendy; Edwin Sibanda | Zendy; Catherine Banana | Zendy; Norbert Muleya | Zendy; Evidence Makombe | Zendy; Paula Littia Jongwe | Zendy; Regina Bhebhe | Zendy; Douglas Mangwanya | Zendy; Janet Dzangare | Zendy; Fungai Hamilton Mudzengerere | Zendy; Collins Timire | Zendy; Enock Wekiya | Zendy; Charles Sandy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevalence, risk factors and treatment outcomes of isoniazid resistant TB in Bulawayo city, Zimbabwe: A cohort study

Author(s) -

Barbara Manyame-Murwira,

Kudakwashe Collins Takarinda,

Pruthu Thekkur,

Bright Payera,

Herbert Mutunzi,

Raiva Simbi,

Nicholas Siziba,

Edwin Sibanda,

Catherine Banana,

Norbert Muleya,

Evidence Makombe,

Paula Littia Jongwe,

Regina Bhebhe,

Douglas Mangwanya,

Janet Dzangare,

Fungai Hamilton Mudzengerere,

Collins Timire,

Enock Wekiya,

Charles Sandy

Publication year - 2020

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.12319

Subject(s) - isoniazid , medicine , tuberculosis , rifampicin , confidence interval , cohort , cohort study , pathology

The isoniazid-resistant TB poses a threat to TB control efforts. Zimbabwe, one of the high TB burden countries, has not explored the burden of isoniazid resistant TB. Hence among all bacteriologically-confirmed TB patients diagnosed in Bulawayo City during March 2017 and December 2018, we aimed to assess the proportion with isoniazid resistant TB and associated factors. Also, we aimed to describe the TB treatment outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research